Credence

Biogen Partners With TRIMTECH in $411M Deal to Develop Neurodegenerative Disease Therapies


Key Points

  • Biogen and TRIMTECH will develop small molecule degraders using TRIMTECH's TRIM21-based platform for neurodegenerative diseases
  • The deal includes up to $32 million in upfront and research milestones and up to $411 million in total potential value, plus royalties
  • Biogen holds an option for a global exclusive license and would assume development and commercialization

TRIMTECH Therapeutics has entered into a strategic collaboration with Biogen to discover and develop small molecule drugs designed to eliminate toxic protein aggregates associated with neurodegenerative diseases. The agreement brings together TRIMTECH’s targeted protein degradation technology and Biogen’s experience in developing treatments for neurological disorders.

The collaboration, structured as a research, option and license agreement, will focus on small molecule degraders built around TRIMTECH’s proprietary TRIM21-based platform. Under the arrangement, Biogen will have the option to obtain a global exclusive license to the compounds generated through the partnership. If it exercises that option, Biogen will assume responsibility for subsequent development and commercialization.

Financial terms include up to $32 million in upfront and research milestone payments for TRIMTECH. The agreement also provides for additional development and commercial milestones that could bring the total potential value to $411 million, in addition to royalties on future product sales.

Dr. Nicki Thompson, CEO of TRIMTECH Therapeutics, describes the agreement as an important milestone for the company and a validation of its progress with TRIM21-based protein degradation. She says the collaboration will combine TRIMTECH’s technology with Biogen’s experience in neurodegenerative disease research, with the shared goal of advancing new treatment possibilities for patients.

TRIMTECH’s approach is based on decades of academic research into TRIM21, an E3 ubiquitin ligase involved in the targeted breakdown of proteins. The company has developed two proprietary degrader technologies, TRIMTAC and TRIMGLUE, designed to selectively target and eliminate disease-associated protein aggregates and oligomers.

A key feature of the technology is its potential to reach the central nervous system (CNS), an important consideration in developing treatments for neurodegenerative conditions. By using small molecules to direct the degradation of toxic proteins rather than simply inhibiting their activity, TRIMTECH aims to address underlying disease mechanisms and expand therapeutic options for patients.

The partnership represents another effort to advance targeted protein degradation as a therapeutic strategy for neurological disorders, an area where the accumulation of abnormal proteins plays a role in several devastating diseases.

For more information, visit: www.trimtechtherapeutics.com.